

Efficacy of *Lepidium Sativum* to act as an anti-diabetic agent

Mishra N.^{1, A-F}, Mohammed A.^{2, A-F}, Rizvi SI.*^{2, A-F}

1. Centre of Food Technology, Institute of Professional Studies, University of Allahabad, Allahabad, U. P. 211002, India
2. Department of Biochemistry, University of Allahabad, Allahabad, U. P. 211002, India

A- Conception and study design; **B** - Collection of data; **C** - Data analysis; **D** - Writing the paper; **E**- Review article; **F** - Approval of the final version of the article

ABSTRACT

Objective: *Lepidium sativum*, commonly known as *chandrashoor* in India, has been used in the Indian traditional medicine system for the treatment of various diseases. The present study was undertaken to investigate the hypoglycemic effect of *Lepidium sativum* in normal and streptozotocin-induced diabetic rats.

Materials and methods: Thirty (30) adult male Wistar rats weighing 157±51g were randomly assigned to five groups of six rats each as Normal control, Diabetic control, Diabetics supplemented with *Lepidium sativum* extract, Diabetics treated with insulin, and Normal rats supplemented with *Lepidium sativum*. All rats were fed with a normal laboratory diet, nutrient rich pellets, and had free access to drinking water. The rats were injected with streptozotocin at a dose of 45 mg/kg body weight intraperitoneally to induce diabetes. The extracts

were then given orally to different groups of rats at a dose of 20mg/kg body weight for 16 days. Thereafter, the rats were sacrificed, and blood samples collected by cardiac puncture were used for the determination of Glucose, Creatinine, Alkaline Phosphatase, Cholesterol, Malondialdehyde level, % DPPH, and FRAP content.

Results: Administration of lepidium extract showed a significant reduction in glucose, creatinine, and alkaline phosphatase levels. Elevated cholesterol level was restored approximately to normal; a significant decrease in malondialdehyde levels was also observed compared to diabetic controls.

Conclusion: *Lepidium sativum* extract shows efficacy in the prevention and management of diabetes mellitus and its related complications.

Keywords: *Lepidium sativum*, diabetes, insulin, streptozotocin, oxidative stress, cholesterol

DOI: 10.5604/01.3001.0010.1811

***Corresponding author:**

Syed Ibrahim Rizvi
Department of Biochemistry, University of Allahabad
Allahabad U. P. 211002, India Ph. +919415305910
e-mail. sirizvi@gmail.com

Received: 02.01.2017

Accepted: 17.03.2017

Progress in Health Sciences

Vol. 7(1) 2017 pp 44-53

© Medical University of Białystok, Poland

INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder of multiple etiologies characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action or both [1]. DM is characterized by hyperglycemia, which usually culminates in several late complications: micro-vascular complications like retinopathy, nephropathy, and peripheral neuropathy; and an increased risk of cardiovascular disease [2].

The International Diabetes Federation [3] estimated the incidence of diabetes projection for the year 2015 to be 419 million adults and is expected to reach 642 million by 2040. Diabetes in all its forms imposes unacceptably high human, social and economic costs on countries at all income levels [4]. Modern and orthodox medicines, currently available for the management and treatment of diabetes mellitus, result in serious side effects such as hepatotoxicity, abdominal pain, flatulence, diarrhea, and hypoglycemia [5, 6]. Due to this fact, researchers are continuously trying to find antidiabetic agents with high efficacy and low side effects for the management and treatment of diabetes. The treatment of diabetes mellitus with insulin and sulphonylureas comes with the underlying consequence of hypoglycemic shock, which might result in fatality [7]. For the reasons stated above, the use of traditional medicine based on plants/plant products is very common in several parts of the world. The WHO has listed 21,000 plants [8] that are used for medicinal purposes around the world, and there are about 800 plants that have been reported to show antidiabetic potential [9].

Lepidium sativum L. (LS) is a fast-growing, edible herb [10] of the Brassicaceae family [11]. The seeds have many biological activities and are used in folk remedies. The seeds are thermogenic, depurative, aphrodisiac, ophthalmic, diuretic, abortive, and contraceptive in nature [12, 13].

Lepidium sativum seeds are rich sources of phytochemicals including phenolic compounds, terpenoids, alkaloids, flavonoids, and organosulfur compounds. It also contains phytosterols and their derivatives, which are known to possess antioxidant potential, anti-cancer, anti-inflammatory, and cardioprotective activity [14-16]. The oil of the *L. sativum* seeds is rich in alpha linolenic acid, and contains an ideal ratio of omega-3 fatty acids and omega-6 fatty acids, which shows cardioprotective and chemopreventive effects [17-19].

Aqueous LS extract has been shown to exhibit hypoglycemic activity in diabetic rats [20]. The present study was carried out in order to evaluate the hypoglycemic effect of aqueous LS extract in normal and streptozotocin (STZ)-induced diabetic rats.

MATERIALS AND METHODS

Plant Material and Preparation of Extract

Lepidium sativum L. seeds were collected from a local market of Allahabad, U.P., India. The seeds were then washed thoroughly under running tap water and then with distilled water; and shade dried and ground into powder. The aqueous extract was prepared in a standardized manner by boiling 1 g of dried powdered LS seeds in 100 ml of distilled water for 10 min. It was further left for 15 min to infuse, then cooled and filtered. The filtrate was lyophilized and the desired dose (milligram of lyophilized aqueous LS extract per kilogram of body weight) was then prepared and re-constituted in 10 ml of distilled water per kilogram of body weight just before oral administration. The aqueous extract dose was 20 mg/kg of body weight daily by oral administration [20].

Experimental Design

The experiment was carried out on 30 male Wistar rats (4 ± 0.5 months old) with an average body weight of 157 ± 51 g. They were housed in a temperature-controlled facility (25 ± 5 °C) with a 12 h light–dark cycle for at least 1 week. All rats were fed with a normal laboratory diet, nutrient rich pellets containing total energy as fat, protein and carbohydrates, and had free access to drinking water. After the stabilization period of one week, the rats were randomly divided into five groups, containing six animals in each group. *Group I: Normal Control* (NC) receiving no treatment/supplementation; *Group II: Diabetic control*: rats were injected a single dose of streptozotocin intraperitoneally. *Group III: Diabetic-induced rats* were administered insulin. *Group IV: Diabetic-induced rats* were administered LS extract via gavage technique (oral route) at 20 mg/kg of body weight/day for 16 days. *Group V: Normal rats* were given only LS extract for 16 consecutive days.

Diabetes was induced by intraperitoneal injection of streptozotocin dissolved in 0.1M cold sodium citrate buffer, pH 4.5, at a dose of 45mg/kg of body weight. After 96 hours, diabetes was confirmed by the determination of fasting blood glucose level with the help of a glucometer (Glucocare TM ultima). Rats with blood glucose of 241-275 mg/dL were considered diabetic and included in the study. All treatments were carried out up to 16 days. Animals from the first group were simultaneously administered water until 16 days.

Biochemical Assays

After the end of the treatment period, the rats were sacrificed under light anesthesia. Blood samples were collected by cardiac puncture into 10 units / ml heparin rinsed anticoagulant syringes, and then red blood cells were pelleted by centrifugation at 800 g for

10 min at 4°C. After the removal of plasma (immediately frozen at -80°C until use for biochemical assays), buffy coat, and the upper 15% of packed red blood cells (PRBCs), the RBCs were washed twice with cold phosphate buffered saline (PBS) (0.9% NaCl and 10 mmolL⁻¹ Na₂HPO₄; pH 7.4) and then used for the experiment.

Lipid profile (ALP, Cholesterol) and creatinine were measured using reagent kits from Erba Diagnostics, Mannheim, Germany. Blood glucose values were determined using an Accu-Check Active Glucometer (Roche Diagnostics, Mannheim, Germany). Plasma lipid peroxidation (MDA) was measured according to the method of Esterbauer and Cheeseman [21], with a slight modification. The total antioxidant potential of the plasma was determined using a modification of the ferric reducing ability of plasma (FRAP) assay, as reported by Benzie and Strain [22].

Statistical Analysis

All values are expressed as mean ±SD. Statistical analysis was conducted using Student's *t*-test and the Mann-Whitney *U* test by using PRISM version 5.01 software. A level of *p*<0.05 was considered statistically significant.

RESULTS

In this study, the anti-hyperglycemic effect of *Lepidium sativum* (LS) aqueous extract was investigated using streptozotocin-induced diabetic rats.

After 16 days of oral administration of aqueous LS extracts, significant reduction in blood glucose levels was observed in the streptozotocin-induced diabetic rats. Blood glucose was significantly elevated (*P* < 0.05) in diabetic rats compared with normal control rats (Figure 1). In diabetic rats, oral administration of aqueous LS extract (20 mg/kg of body weight) lowered blood glucose significantly (*P* < 0.05).

Cholesterol level was found to be increased significantly (*P* < 0.05) in diabetic rats compared with the normal control rats. A significant decrease was observed after the administration of LS extract in diabetic rats (Figure 2).

In the present study, the creatinine level increased significantly (*p*< 0.05) in diabetic rats when compared with the normal control rats. Oral administration of aqueous extract of LS offered a significant decrease in the creatinine level compared with diabetic rats (Figure 3).

Alkaline phosphatase was shown to be present in all body tissues with higher amounts in the liver, bile ducts, and bone. Elevation of alkaline phosphatase in diabetic conditions is an intrinsic feature of diabetes [23], which corroborates the findings of this work. The induction of diabetes with streptozotocin leads to the elevation of alkaline phosphatase in the diabetic group rats. Treatment of rats in the diabetic group with LS significantly decreased alkaline phosphatase (*p*<0.05) when compared with rats of the diabetic group (Figure 4).




Figure 1. Effect of aqueous extract of *Lepidium sativum* on blood glucose levels of STZ - induced diabetic rats




Figure 2. Effect of aqueous extract of *Lepidium sativum* supplementation on plasma cholesterol levels of STZ - induced diabetic rats




Figure 3. Effect of aqueous extract of *Lepidium sativum* supplementation on plasma creatinine levels of STZ - induced diabetic rats




Figure 4. Effect of aqueous extract of *Lepidium sativum* supplementation on plasma alkaline phosphatase levels of STZ - induced diabetic rats

In the present study, it was observed that mean value of lipid peroxide (MDA) and DPPH% was significantly increased in the diabetic group compared

with the control, which significantly decreased with the administration of aqueous LS extract (Figures 5 and 7).




Figure 5. Effect of aqueous extract of *Lepidium sativum* supplementation on MDA levels of STZ - induced diabetic rats

Figure 6 depicts a significant decrease in FRAP levels in the diabetic group compared with the controls. Oral

administration of *Lepidium sativum* extract restored the FRAP level in the diabetic group close to normal.




Figure 6. Effect of aqueous extract of *Lepidium sativum* supplementation on FRAP levels of STZ - induced diabetic rats




Figure 7. Effect of aqueous extract of *Lepidium sativum* supplementation on DPPH % inhibition of STZ - induced diabetic rats

DISCUSSION

Insulin and sulphonylureas, are used most commonly for the treatment of diabetes, which may increase the risk of hypoglycemia and lead to fatal

consequences. Hence, there is a need to search for safer and more effective alternatives [7].

The decrease in blood sugar levels after *Lepidium sativum* administration may be due to the presence of linolenic acids. The presence of oleic acids

(30.6 wt %) and linolenic acids (29.3 wt %) had been reported in LS oil [23]. LS seed oil contains high concentrations of tocopherols. However, the primary phytosterols reported in LS are sitosterol, campesterol, and avenasterol [24]. The glucose lowering action might also be the result of LS extract stimulating the surviving β -cells of islets of Langerhans to release more insulin [25]. Flavonoids and glycosides have been demonstrated to be able to act and stimulate pancreatic β -cells to secrete insulin and enhance glucose metabolism [26].

Flavonoids, coumarins, sulphur glycosides, triterpenes, sterols, and various imidazole alkaloids are some of the phytochemicals present in LS [27]; with lepidine and semilepidine being the major alkaloids [28]. These alkaloids have been demonstrated to possess hypoglycemic activity [29-31]. Aqueous LS extract has been reported to affect glucose homeostasis by inhibiting endogenous glucose production in the liver [32], inhibiting renal glucose reabsorption through the alteration of renal glucose transporter (SLGT1) expression in the kidneys [33], increasing both glucose uptake [34] and glucose intracellular metabolism [35, 36] in the muscle and adipose tissues. Finally, the inhibition of intestinal glucose absorption could also be involved in this observed hypoglycemic activity of LS [37].

Lipid profile results are in agreement with the results obtained by [38], who reported that the lipid profile of hypercholesterolemic animals was significantly higher than control rats for total lipid, total cholesterol, triglyceride, LDL-C and VLDL-C, while only HDL-C was significantly lower in hypercholesterolemic rats than in control rats [24]. Serum cholesterol and triglyceride levels are also strongly related to the degree of diabetic control in rats. The increased total cholesterol, triglyceride and LDL-cholesterol levels observed in diabetic rats may be the result of impaired liver function caused by damage done by STZ, which acts either directly or indirectly by enhancing the serum glucose level [39].

Yadav et al, [40] showed that protective and curative treatment of ethanolic extract of LS seeds with cisplatin significantly reduced the level of urea and creatinine that indicates an increased glomerular filtration rate (GFR). Indeed, in people with diabetes, GFR is usually less than half of normal [41]. The increased urea and creatinine levels suggest the reduction of the glomerular filtration rate [42].

STZ treatments play a significant role in the alteration of liver functions, because the activity of aspartate aminotransferase (AST) and alanine transaminase (ALT) was significantly higher than those of normal values [43]. In diabetic rats, the activity of serum ALP was significantly increased by 72.31% from normal levels; therefore, the increase in the activity of ALP in serum is mainly due to the leakage of these

enzymes from the liver cytosol into the blood stream [44], which is an indication of the hepatotoxic effect of streptozotocin. Administration of LS extract to diabetic rats in this study significantly reduced ALP activity towards normal values.

Sakran et al. [45] observed a reduction in paracetamol-induced hepatotoxicity in male rats and found that 5,6-dimethoxy-2', 3'-methylenedioxy-7-C- β -d-gluco-pyranosyl isoflavone, isolated from the seeds of *Lepidium sativum* L. was effective in reducing the damage and toxicity effects on liver cells with a significant improvement of total antioxidant capacity and normalizing the levels of liver enzymes GSH, SOD, GPX, GST and CAT compared with the control group.

The reducing capacity of *Lepidium sativum* seed extracts can be used as a significant indicator of its potential antioxidant activity [46]. The result reveals that *Lepidium sativum* is a rich source for phyto-constituents like phenolic compounds, vitamin E, and terpenoids, and can be used as a potent antioxidant and antilipidemic agent [47].

Diabetic complications develop with increased activity of free radical-induced lipid peroxidation and accumulation of lipid peroxidation products. Free radicals react with polyunsaturated fatty acids (PUFA) to form peroxides, thus degrading lipids and releasing malondialdehyde (MDA), which is a stable product of lipid peroxidation, and measured as an index of lipid peroxidation.

Measuring total plasma antioxidant capacity using the FRAP method is a guide to knowing the antioxidant status, which is often low in diabetics. The biological system has a natural mechanism to counteract the effect of reactive oxygen species (ROS) thereby preventing oxidative damage to body cells. Oxidative stress in diabetes coexists with a reduction in antioxidant power [48]. The natural antioxidant defense mechanism of the biological system includes the enzymes catalase, glutathione peroxidase, superoxide dismutase; biomolecules like albumin and ferritin; and some other molecules such as ascorbic acid, β carotene, GSH, uric acid, and bilirubin. The total endogenous antioxidants and ones consumed from food sources give the total antioxidant capacity of the biological system. FRAP gives the total antioxidant capacity in the biological system and is a good indicator of the body's ability to protect itself from ROS [49]. This experimental work indicates that FRAP values in the diabetic control group was significantly lower compared with the normal control group. The administration of LS extract increased FRAP values, as noticed in the treated groups. This might be as a result of LS extract containing β carotene and ascorbic acid, which might have contributed to the total antioxidant capacity as given by FRAP.

Al-Sheddi et al. (2016) [50] observed that *Lepidium sativum* extract (LSE) at 25 μ g/ml

concentration significantly inhibited the induction of ROS generation (45%) and lipid peroxidation (56%), and increased the mitochondrial membrane potential (55%) and GSH levels (46%). The study suggests the cytoprotective and antioxidative effects of LSE against H₂O₂-induced toxicity in HepG2.

CONCLUSION

By means of regulating the plasma redox balance, *Lepidium sativum* seeds have been observed to reduce the complications of diabetes developed due to oxidative stress/ free radical accumulation. LS seed extract has also been found effective in regulating blood glucose, plasma creatinine, and plasma alkaline phosphatase levels, thereby showing improved renal function and depicting hepatoprotective potential in LS. Maintaining the lipid profile in the normal range and reducing the increased levels of plasma MDA showed the anti-lipid peroxidation and cardioprotective action of LS. Our findings provide a scientific validation of the use of *Lepidium sativum* as an adjunct therapy in diabetes.

Acknowledgement

Centre of Food Technology and Department of Biochemistry, University of Allahabad.

Conflicts of interest

Authors declare no conflicts of interest.

REFERENCES

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2010 Jan; 33(Suppl 1):S62–S9.
2. Rothberg AE, Halter JB. Obesity and diabetes in an aging population: time to rethink definitions and management. *Clin Geriatr Med*. 2015 Feb;31(1):1–15.
3. International Diabetes Federation, *Diabetes Atlas Seventh edition* 2015.
4. Cheng AY. Clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. *Can J Diabetes*. 2013 Apr;37(Suppl 1): S1-S3.
5. Singh SK, Rai PK, Jaiswal D, Watal G. Evidence-based Critical Evaluation of Glycemic Potential of *Cynodon dactylon*. *Evid Based Complement Alternat Med*. 2008 Dec;5(4):415-20.
6. Fujisawa T, Ikegami H, Inoue K, Kawabata Y, Ogihara T. Effect of two α -glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. *Metabolism*. 2005 Mar;54(3):387-90.
7. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. *Nat Rev Endocrinol*. 2014 Dec;10(12):711-22.
8. World Health Organization. “Traditional medicine-growing needs and potential,” WHO Policy Perspective on Medicines. 2002 May;2:1-6.
9. Patil R, Patil R, Ahirwar B, Ahirwar D. Current status of Indian medicinal plants with antidiabetic potential: a review. *Asian Pac J Trop Biomed*. 2011 Oct;1(2):S291-8.
10. Sharma RK, Vyas K, Manda H. Evaluation of antifungal effect on ethanolic extract of *Lepidium sativum* seed. *Int J Phytopharmacol*. 2012; 3(2):117-120.
11. Prajapati VD, Maheriya PM, Jani GK, Patil PD, Patel BN. *Lepidium sativum* L.: A current addition to the family of Mucilage and its applications. *Int J Biol Macromol*. 2014 Apr;65:72–80.
12. Dugasani SL, Balijepalli MK, Rao MP. Growth inhibition and induction of apoptosis in estrogen receptor-positive and negative human breast carcinoma cells by *Adenocalymma alliaceum* flowers. *Curr Trends Biotechnol Pharm*. 2009 July; 3(3):278-86.
13. Gokavi SS, Malleshi NG, Guo M. Chemical composition of garden cress (*Lepidium sativum*) seeds and its fractions and use of bran as a functional ingredient. *Plant Foods for Human Nutr (Formerly Qualitas Plantarum)*. 2004 Sept;59(3): 105–11.
14. Hudaib M, Mohammad M, Bustanji Y, Tayyem R, Yousef M, Abuirjeie M, Aburjai T. Ethnopharmacological survey of medicinal plants in Jordan, Mujib nature reserve and surrounding area. *J Ethnopharmacol*. 2008 Oct;120(1):63–71.
15. Hardman WE, Avula CPR, Fernandes G, Cameron IL. Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer enografts. *Clin Cancer Res*. 2001 Jul;7(7):2041–9.
16. Conforti F, Ioele G, Statti GA, Marrelli M, Ragno G, Menichini F. Antiproliferative activity against human tumor cell lines and toxicity test on Mediterranean dietary plants. *Food Chem Toxicol*. 2008 Oct;46(10):3325–32.
17. Kassie F, Uhl M, Rabot S, Grasl-Kraupp B, Verkerk R, Kundi M, Chabicovsky M, Schulte-Hermann R, Knasmüller S. Chemoprevention of 2-amino-3-methylimidazo[4,5-f] quino-line (IQ)-induced colonic and hepatic preneoplastic lesions in the F344 rat by cruciferous vegetables administered simultaneously with the carcinogen. *Carcinogenesis*. 2003 Feb;24(2):255–61.
18. Khan N, Adhami VM, Mukhtar H. Apoptosis by dietary agents for prevention and treatment of cancer. *Biochem Pharmacol*. 2008 Dec;76(11): 1229–33.

19. Merlin NJ, Parthasarathy V, Santhosh kumar TR. Induction of apoptosis in human breast cancer cell line MCF-7 by phytochemicals from *Gmelina asiatica*. Afr J Biotechnol. 2010 July;9(28):4451–6.
20. Eddouks M, Maghrania M, Zeggwagh NA, Michel JB. Study of the hypoglycaemic activity of *Lepidium sativum* L. aqueous extract in normal and diabetic rats. J Ethnopharmacol. 2005 Feb;97(2):391–5.
21. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malondialdehyde and 4-hydroxynonenal. Methods Enzymol. 1990 Dec;186:407–13.
22. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “Antioxidant Power”: The FRAP assay. Anal. Biochem. 1996 July;239(1):70–6.
23. Bryan RM, Shailesh NS, Jill KW, Steven, FV, Roque LE. Composition and physical properties of cress (*Lepidium sativum* L.) and field pennycress (*Thlaspi arvense* L.) oils. Indus Crops and Prods. 2009 March;30:199–205.
24. Amawi K, Aljama A. Effect of *Lepidium sativum* on lipid profiles and Blood Glucose in Rats. J Phys Pharm Adv. 2012 Aug;2(8):277–81.
25. Saravanan R, Babu KP, Ramachandran V. Effect of Rebaudioside A, a diterpenoid on glucose homeostasis in STZ-induced diabetic rats. J Physiol and Biochem. 2012 Sep;68(3):421–31.
26. Hii CST, Howell SL. Effect of flavonoids in insulin secretion and Ca^{2+} handling in rats islets of Langerhans. J Endocrinol. 1985 Oct;107(1):1–8.
27. Radwan HM, El-Missiry MM, Al-Said WM, Ismail AS, Abdel-Shafeek KA, Seif-El-Nasr MM. Investigation of the glucosinolates of *Lepidium sativum* growing in Egypt and their biological activity. Res J Med Med Sci. 2007; 2(2):127–32.
28. Maier UH, Gundlach H, Zenk MH. Seven imidazole alkaloids from *Lepidium sativum*. Phytochemistry. 1998 Nov;49(6):1791–5.
29. Anntia BS, Okokon JE. Phytochemical composition and antidiabetic activity of ethanol root extract of *Nauclea latifolia*. J Phytopharmacol. 2014 Jan-Feb; 3(1):52–6.
30. Tiong SH, Looi CY, Hazni H, Arya A, Paydar M, Wong W, Cheah S, Mustafa M, Awang K. Antidiabetic and Antioxidant Properties of Alkaloids from *Catharanthus roseus* (L.) G. Don. Molecules. 2013 Aug;18(8):9770–84.
31. Shukla A, Bigoniya P, Srivastava B. Hypoglycemic Activity of *Lepidium sativum* Linn Seed Total Alkaloid on Alloxan Induced Diabetic Rats. Res J Med Plant. 2012 Sep;6(8):587–96.
32. Eddouks M, Jouad H, Maghrani M, Lemhadri A, Burcelin R. Inhibition of endogenous glucose production accounts for hypoglycemic effect of *Spergularia purpurea* in streptozotocin mice. Phytomedicine. 2003;10(6-7):594–9.
33. Adachi T, Yasuda K, Okamoto Y, Shihara N, Oku A, Ueta K, Kitamura K, Saito A, Iwakura I, Yamada Y, Yano H, Seino Y, Tsuda K. T-1095, a renal Na^{+} -glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism. 2000 Aug;49(8):990–5.
34. Luo J, Rizkalla SW, Vidal H, Oppert JM, Colas C, Boussairi A, Guerre-Millo M, Chapuis AS, Chevalier A. Moderate Intake of n-3 Fatty Acids for 2 Months Has No Detrimental Effect on Glucose Metabolism and Could Ameliorate the Lipid Profile in Type 2 Diabetic Men: Results of a controlled study. Diabetes Care. 1998 May;21(5):717–24.
35. Zhang XF, Tan BK. Antihyperglycaemic and Anti-Oxidant Properties of *Andrographis paniculata* in Normal and Diabetic Rats. Clin Exp Pharmacol Physiol. 2000 May-June;27(5-6):358–63.
36. Peungvicha P, Thirawarapan SS, Tamsiririrkul R, Watanabe H, Prasain JK, Kadota S. Hypoglycemic effect of the water extract of *Piper sarmentosum* in rats. J Ethnopharmacol. 1998 Feb; 60(1):27–32.
37. Patel K, Srinivasan K. Plant foods in the management of diabetes mellitus: vegetables as potential hypoglycaemic agents. Nahrung, 1997 April;41(2):68–74.
38. Das S, Samal SC, Baliarsinha AK, Tripathy BB. Lean (underweight) NIDDM – Peculiarities and differences in metabolic and hormonal status- A pilot study. J Assoc Physicians India 1995 May; 43(5):339–42.
39. Yao HT, Huang SY, Chiang MT. Comparative study on hypoglycemic and hypocholesterolemic effects of high and low molecular weight chitosan in streptozotocin-induced diabetic rats. Food Chem Toxicol. 2008 May; 46(5):1525–34.
40. Yadav YC, Srivastava DN, Seth AK, Gupta VD, Yadav KS, Kumar S. Nephroprotective and curative activity of *Lepidium sativum* L. seeds in albino rats using cisplatin induced nephrotoxicity. Pharmacology. 2009 Dec;3:640–6.
41. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985 Nov; 28(5):830–8.
42. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose Vitamin administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology. 2004 Feb; 195(2-3):221–30.
43. Sheweita SA, El-Gabar MA, Bastawy M. Carbon tetrachloride changes the activity of cytochrome P450 system in the liver of male rats: role of antioxidants. Toxicology. 2001 Dec;169(2):83–92.
44. Mansour HA, Al-Sayeda AN, Yousef MI, Sheweita S. Biochemical study on the effects of some

- Egyptian herbs in alloxan-induced diabetic rats. Toxicology. 2002 Jan;170(3):221-8.
45. Sakran M, Selim Y, Zidan N. A new isoflavonoid from seeds of *Lepidium sativum* L. and its protective effect on hepatotoxicity induced by paracetamol in male rats. Molecules. 2014 Sep; 19(10):15440-51.
 46. Nada S. Effect of seeds extraction of *Lepidium sativum* on zinc and iron elements and some biochemical parameters in serum of white male rabbits. Euphrates J Agr Sci. 2013;5(1):23-35.
 47. Kousar S, Jahan N, Rehman K, Nosheen S. Antilipidemic activity of *Coriandrum sativum*. Bioscience Research. 2011 Aug;8(1):8-14.
 48. Alireza N, Mohammad B, Mohsen S, Ali F, Azim A. Attenuation of oxidative stress in streptozotocin-induced diabetic rats by eucalyptus globulus. Indian J Clin Biochem. 2009 Oct;24(4):419-25.
 49. Pinzani P, Petruzzi E, Orlando C, Gallai R, Serio M, Pazzagli M. Serum antioxidant capacity in healthy and diabetic subjects as determined by enhanced chemiluminescence. J Biolumin Chemilumin. 1998 Sep-Oct;13(5):321-25.
 50. Al-Sheddi ES, Farshori NN, Al-Oqail MM, Musarrat J, Al-Khedhairy AA, Siddiqui MA. Protective effect of *Lepidium sativum* seed extract against hydrogen peroxide-induced cytotoxicity and oxidative stress in human liver cells (HepG2). Pharm Bio. 2016 Apr;54(2):314-21.